Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/23500
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoukos, D. H.en
dc.date.accessioned2015-11-24T19:33:08Z-
dc.date.available2015-11-24T19:33:08Z-
dc.identifier.issn1527-7755-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23500-
dc.rightsDefault Licence-
dc.subjectAntibodies, Monoclonal/*therapeutic useen
dc.subjectAntibodies, Monoclonal, Humanizeden
dc.subjectAntineoplastic Agents/therapeutic useen
dc.subjectBreast Neoplasms/*drug therapy/enzymology/metabolism/*pathologyen
dc.subjectDisease-Free Survivalen
dc.subjectFemaleen
dc.subjectHumansen
dc.subjectNeoplasm Stagingen
dc.subjectReceptor, erbB-2/*antagonists & inhibitors/immunologyen
dc.subjectReceptors, Estrogen/metabolismen
dc.subjectReceptors, Progesterone/metabolismen
dc.titleBeyond HER2 and trastuzumab: heterogeneity, systems biology, and cancer origin research may guide the future for personalized treatment of very early but aggressive breast canceren
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.primary10.1200/JCO.2009.27.7061-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/20406920-
heal.identifier.secondaryhttp://jco.ascopubs.org/content/28/17/e279.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2010-
heal.journalNameJ Clin Oncolen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Files in This Item:
File Description SizeFormat 
Roukos-2010-Beyond HER2 and tras.pdf52 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons